Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.59 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | TYK2 | P29597 | 1/20 | 0.58 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.58 |
| ▸ | F12 | P00748 | 1/20 | 0.58 |
| ▸ | PLAU | P00749 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.56 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29238957 | 0.98 | RAB9A (0.57) | RAB9ANPC1JAK2TYK2SIRT2 | |
| SCHEMBL18906078 | 0.88 | RAB9A (0.55) | RAB9ANPC1SIRT2F2F12 | |
| SCHEMBL10720732 | 0.85 | RAB9A (0.71) | RAB9ANPC1MEN1KMT2APKM | |
| SCHEMBL4542768 | 0.84 | BCAT2 (0.58) | RAB9ANPC1JAK2TYK2F2 | |
| SCHEMBL17675284 | 0.84 | RAB9A (0.55) | RAB9ANPC1SIRT2MEN1KMT2A | |
| SCHEMBL18906050 | 0.83 | PKM (0.59) | RAB9ANPC1SIRT2KCNK3KCNK9 | |
| SCHEMBL29744073 | 0.83 | F2 (0.58) | RAB9ANPC1F2F12PLAU | |
| SCHEMBL20641503 | 0.83 | F2 (0.58) | RAB9ANPC1F2F12PLAU | |
| SCHEMBL3299661 | 0.83 | ADORA1 (0.70) | RAB9ANPC1JAK2TYK2F2 | |
| SCHEMBL18398718 | 0.82 | LMNA (0.58) | RAB9ANPC1MEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107898-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2016-12-28 | — | — | EP | claimed |
| WO-2015124932-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-08-27 | — | — | WO | claimed |
| CN-103073902-B | Polymer-modified asphalt and preparation method thereof | CHINA NAT OFFSHORE OIL CORP | 2015-01-28 | — | — | CN | claimed |
| EP-2734522-A1 | 4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS | Merck Sharp & Dohme B.V. (NL) | 2014-05-28 | — | — | EP | claimed |
| CN-103073902-A | Polymer-modified asphalt and preparation method thereof | CHINA NAT OFFSHORE OIL CORP | 2013-05-01 | — | — | CN | claimed |
| WO-2013010868-A1 | 4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS | MSD OSS B.V. (NL) | 2013-01-24 | — | — | WO | claimed |
| CN-115043841-B | Preparation and application of heterocyclic compound serving as BTK inhibitor | 药雅科技(上海)有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-116606246-A | Silver complex antibacterial agent with aromatic amide structure-containing nitrogen heterocyclic derivative as ligand, and preparation method and application thereof | 烟台哈尔滨工程大学研究院 | 2023-08-18 | — | — | CN | disclosed |
| CN-115043841-A | Preparation and application of heterocyclic compound as BTK inhibitor | 药雅科技(上海)有限公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-114276270-A | Synthesis method of compound with amido bond | 湖北文理学院 | 2022-04-05 | — | — | CN | disclosed |
| CN-109053558-B | Synthesis method of N-heterocyclic amide derivative | 贵州大学 | 2022-02-18 | — | — | CN | disclosed |
| CN-113773264-A | Pyrimidine amide compound applied to herbicide and preparation method thereof | 池州飞昊达化工有限公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-107950527-B | Safener and composition for resisting amide herbicide phytotoxicity of grains | 湖南省农业生物技术研究中心 | 2020-11-17 | — | — | CN | disclosed |
| WO-2010134939-A2 | MAMMALIAN GENES INVOLVED IN INFECTION | Zirus, Inc. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7754717-B2 | Bis-aryl amide compounds and methods of use | AMGEN INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20070072862-A1 | Bis-aryl amide compounds and methods of use | AMGEN INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2003010153-A1 | N-ALKYL-N-PHENYLHYDROXYLAMINE COMPOUNDS CONTAINING METAL CHELATING GROUPS, THEIR PREPARATION AND THEIR THERAPEUTIC USES | SAMSUNG ELECTRONICS CO. LTD. (KR) | 2003-02-06 | — | — | WO | disclosed |
| WO-1999029670-A2 | AMINOCARBONYLTETRALIN AND DIHYDRONAPHTALENE DERIVATES AS THROMBIN INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-06-17 | — | — | WO | disclosed |
| EP-0151826-B1 | 4-[(Bicyclic heterocyclyl)-methyl and -hetero]-piperidines | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072862-A1 | Bis-aryl amide compounds and methods of use | LCK, BTK, IRAK1 | RAB9A 2344/4885NPC1 4394/4885JAK2 30/4885 |
| US-20100234373-A1 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | LCK, BTK, IRAK1 | RAB9A 2344/4885NPC1 4394/4885JAK2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.